One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Processa Pharmaceuticals logo
Processa Pharmaceuticals PCSA
$ 1.59 -4.22%
report update icon

Quarterly report 2026-Q3
added 11-13-2026

Processa Pharmaceuticals Income Statement 2025-2011 | PCSA

Brief overview of income trends at Processa Pharmaceuticals

This overview is based on financial performance over the past five years. The revenue attributed to Processa Pharmaceuticals moved from 20 thousand dollars to 5 thousand dollars between the two endpoints. The five-year change reached −75%, while CAGR stood at −24.2%. The negative rate indicates weakening core operations.

The gross result shifted from $20 thousand to $5 thousand, or −75%. Comparing the endpoints gives gross margins of 100% and 100%. Gross profitability remained broadly stable.

EBITDA changed from −1.1 million dollars to −71.4 thousand dollars (+93.6%). EBITDA grew faster than revenue, indicating positive operating leverage. Comparing the endpoints gives EBITDA margins of −5550% and −1427.3%. A wider margin confirms stronger operating efficiency.

Net income moved from −$940 thousand at the start to −$336 thousand at the end. The negative result improved without reaching break-even.

Conclusion

The results present an uneven picture without one dominant signal. The financial profile benefits from steady gross profitability, net-income growth and an improving EBITDA margin. The weaker side of the profile includes weak sales momentum and a narrow EBITDA buffer. Investors should continue to monitor margins, costs, and earnings quality.

Annual Income Statement Processa Pharmaceuticals

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

4.14 M 387 K 3.11 M 371 K 58.7 M 35.2 M 45.6 M 119 M 134 M 1.66 M 4.41 M 19 M - - -

Shares

1.31 M 122 K 1.31 M 805 K 15.3 M 5.59 M 5.53 M 5.33 M 4.66 M 225 K 225 K 181 K - - -

Historical Prices

3.16 3.16 2.37 0.46 3.83 11.4 9.75 18.2 21 7.4 19.6 106 - - -

Net Income

-13.6 M -11.9 M -11.1 M -27.4 M -11.4 M -14.4 M -3.36 M -3.77 M -1.86 M -336 K -3.35 M -4.53 M -3.07 M -2.44 M -940 K

Revenue

- - - - - - - - - 5 K 113 K 200 K 312 K 192 K 20 K

Gross Profit

- - - - - - - - - 5 K -12.5 K 87 K 124 K 58.9 K 20 K

Operating Income

-14 M -12.1 M -11.5 M -27.5 M -12.1 M -15.1 M -3.94 M -4.52 M -1.8 M -1.92 M - - - - -

Interest Expense

- - - - 362 281 K 36.7 K 161 K 59.1 K 245 K 236 K 315 K -110 K -171 K -

EBITDA

-14 M -12.1 M -11.5 M -26.7 M -12.1 M -5.63 M -3.13 M -3.89 M -1.8 M -71.4 K -748 K -2.49 M -2.55 M -2.16 M -1.11 M

Operating Expenses

14 M 12.1 M 11.5 M 27.5 M 12.1 M 6.44 M 3.94 M 4.52 M 1.8 M 76.5 K 975 K 3.03 M 3.09 M 2.33 M 790 K

General and Administrative Expenses

6.18 M 4.78 M 5.66 M 8.76 M 4.69 M 3.26 M 1.61 M 1.44 M 876 K 70 K 945 K - - - 610 K

All numbers in USD currency

Quarterly Income Statement Processa Pharmaceuticals

2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

2.97 M 2.75 M 2.62 M 336 K 1.9 M 629 K 374 K 3.7 M 3.28 M 2.98 M 2.47 M 32.3 K 1.35 M 1.35 M 1.14 M -15.2 M 16.2 M 15.9 M 15.8 M 142 K 15.5 M 15.4 M 14.6 M 14.2 M 5.59 M 5.52 M 5.52 M -5.34 K 5.53 M 5.53 M 5.53 M -31.5 M 38.7 M 36.6 M 35.3 M 35.1 M 31.7 M 31.7 M 11 M 31.7 M 11 M 11 M 11 M 11 M 11 M 11 M 11 M 11 M 8.43 M 8.4 M 8.26 M 8.08 M 7.84 M 2.23 M 1.9 M - 1.75 M 1.75 M - - - - -

Net Income

-183 M -3.27 M -3.38 M -3.36 M -3.44 M -3.93 M -2.83 M - -3.38 M -3.01 M -2.73 M -2.4 M -2.08 M -2.61 M -4.02 M -13 M -6.02 M -5.16 M -3.23 M -3.18 M -2.99 M -3.16 M -2.1 M - -3.07 M -733 K -874 K -1.28 M -864 K -969 K -751 K - -853 K -1.21 M -1.1 M -634 K -204 K -53.6 K -86.2 K -102 K -79.2 K -53.9 K -144 K - -296 K -2.05 M -645 K - -792 K -851 K -1.34 M - -719 K -727 K -816 K - -602 K -475 K - - - - -

Revenue

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 5 K - 5 K 5 K 5 K - 17.6 K 32.8 K 32.8 K - 16.6 K 77 K 7.44 K - 119 K 96 K 19.2 K - 48.6 K 97 K - - - - -

Gross Profit

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 5 K - 5 K 5 K 5 K - 15.5 K 9.03 K 12.8 K - 27.3 K 42.6 K 11.2 K - 45.5 K 35.8 K 7.08 K - 15.1 K 43.2 K - - - - -

Operating Income

-184 M -2.34 M -3.33 M -3.7 M -3.49 M -3.95 M -2.85 M - -3.42 M -3.08 M -2.81 M -2.47 M -2.17 M -2.71 M -4.11 M -13.1 M -6.06 M -5.17 M -3.23 M -3.37 M -3.11 M -3.46 M -2.19 M - -2.96 M -802 K -986 K -912 K -1 M -1.14 M -883 K -742 K -1.06 M -1.43 M -1.29 M -575 K -713 K -280 K -234 K - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

- - - - - - - - - 71.7 K - - - 102 K 83.5 K - - 7.38 K 1.58 K - - 362 362 - 186 K 19.3 K 17.2 K 26.7 K -768 6.1 K 4.6 K 6.83 K 8.32 K 58.3 K 87.7 K 59.1 K 44.2 K 63.4 K 61.9 K 63.3 K 63.3 K 62.6 K 56.1 K - 55 K 47.7 K 35.3 K - 130 K 113 K -60.1 K - -45.4 K -33.8 K -15.9 K - -34.7 K -69.9 K - - - - -

EBITDA

-184 M -2.34 M -3.33 M -3.7 M -3.49 M -3.95 M -2.85 M - -3.42 M -3.08 M -2.81 M -2.47 M -2.17 M -2.71 M -4.11 M -12.9 M -5.86 M -4.97 M -3.03 M -3.17 M -2.92 M -3.26 M -1.99 M - -2.95 M -603 K -787 K -713 K -805 K -938 K -684 K -543 K -863 K -1.23 M -1.29 M -571 K -716 K -280 K -234 K - 159 159 159 - 10.1 K 23.9 K 19.1 K - 22.4 K 23.4 K 21.8 K - 14.5 K 13.2 K 13 K - 4.68 K 715 - - - - -

Operating Expenses

- - 3.33 M - - - - - - - - - - - - 13.1 M 6.06 M 5.17 M 3.23 M 3.37 M 3.11 M 3.46 M 2.19 M - 2.96 M 802 K 986 K 912 K 1 M 1.14 M 883 K 742 K 1.06 M 1.43 M 1.29 M 575 K 713 K 280 K 13.7 K -17.9 K 4.97 K 8.98 K 80.5 K - 140 K 1.89 M 471 K - 689 K 781 K 1.3 M - 720 K 729 K 808 K - 583 K 448 K - - - - -

General and Administrative Expenses

4.29 M 1.69 M 1.52 M 1.59 M 1.83 M 1.5 M 1.26 M - 1.14 M 1.35 M 1.27 M 1.15 M 1.02 M 1.03 M 2.48 M 2.63 M 2.92 M 2.03 M 1.18 M 1.3 M 1.34 M 1.33 M 717 K - 423 K 375 K 484 K 396 K 419 K 410 K 398 K 134 K 451 K 351 K 470 K 384 K 255 K 119 K 13.6 K -18.2 K 4.4 K 3.28 K 80.5 K - 84.2 K 362 K 459 K - 677 K 712 K 805 K - 664 K 666 K 737 K - 519 K 300 K - - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company Processa Pharmaceuticals (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Galectin Therapeutics Galectin Therapeutics
GALT
$ 2.68 -4.63 % $ 171 M usaUSA
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
CORT
$ 63.61 -2.11 % $ 6.61 B usaUSA
Progenity, Inc. Progenity, Inc.
PROG
- -3.47 % $ 164 M usaUSA
Genprex Genprex
GNPX
$ 1.46 -12.87 % $ 1.36 M usaUSA
Strongbridge Biopharma plc Strongbridge Biopharma plc
SBBP
- 1.52 % $ 136 M usaUSA
Nektar Therapeutics Nektar Therapeutics
NKTR
$ 30.23 -7.1 % $ 510 M usaUSA
Innate Pharma S.A. Innate Pharma S.A.
IPHA
$ 0.87 -7.57 % $ 77.9 M franceFrance
Seneca Biopharma, Inc. Seneca Biopharma, Inc.
SNCA
- -1.19 % $ 28.7 M usaUSA
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 60.42 -1.64 % $ 11.6 B usaUSA
Matinas BioPharma Holdings Matinas BioPharma Holdings
MTNB
$ 0.75 -9.23 % $ 4.11 M usaUSA
Enanta Pharmaceuticals Enanta Pharmaceuticals
ENTA
$ 7.6 -4.82 % $ 220 M usaUSA
Milestone Pharmaceuticals Milestone Pharmaceuticals
MIST
$ 0.38 -5.66 % $ 40.4 M canadaCanada
Lipocine Lipocine
LPCN
$ 1.47 -2.33 % $ 8.01 M usaUSA
Seres Therapeutics Seres Therapeutics
MCRB
$ 1.25 -6.02 % $ 11.1 M usaUSA
Oramed Pharmaceuticals Oramed Pharmaceuticals
ORMP
$ 3.58 -2.98 % $ 148 M israelIsrael
Madrigal Pharmaceuticals Madrigal Pharmaceuticals
MDGL
$ 378.19 -4.68 % $ 8.48 B usaUSA
CEL-SCI Corporation CEL-SCI Corporation
CVM
$ 1.2 -18.37 % $ 9.62 M usaUSA
Inventiva S.A. Inventiva S.A.
IVA
$ 3.14 -9.13 % $ 188 M franceFrance
MeiraGTx Holdings plc MeiraGTx Holdings plc
MGTX
$ 7.98 -1.97 % $ 642 M usaUSA
Teva Pharmaceutical Industries Limited Teva Pharmaceutical Industries Limited
TEVA
$ 39.21 1.76 % $ 44.9 B israelIsrael
Eton Pharmaceuticals Eton Pharmaceuticals
ETON
$ 60.77 -0.96 % $ 1.64 B usaUSA
IDEAYA Biosciences IDEAYA Biosciences
IDYA
$ 25.52 -2.48 % $ 2.26 B usaUSA
Protalix BioTherapeutics Protalix BioTherapeutics
PLX
$ 2.89 -5.56 % $ 227 M israelIsrael
Lantern Pharma Lantern Pharma
LTRN
$ 0.25 -13.67 % $ 2.72 M usaUSA
Foghorn Therapeutics Foghorn Therapeutics
FHTX
$ 1.71 -3.93 % $ 108 M usaUSA
Ocugen Ocugen
OCGN
$ 0.77 4.74 % $ 241 M usaUSA
Oncolytics Biotech Oncolytics Biotech
ONCY
$ 0.35 -10.37 % $ 33.6 M canadaCanada
Minerva Neurosciences Minerva Neurosciences
NERV
$ 2.03 -4.25 % $ 17.2 M usaUSA
Neurocrine Biosciences Neurocrine Biosciences
NBIX
$ 150.5 -3.89 % $ 15 B usaUSA
Nanobiotix S.A. Nanobiotix S.A.
NBTX
$ 26.12 -1.7 % $ 1.25 T franceFrance
Prothena Corporation plc Prothena Corporation plc
PRTA
$ 8.12 -3.33 % $ 437 M usaUSA
Mereo BioPharma Group plc Mereo BioPharma Group plc
MREO
$ 0.26 -5.45 % $ 207 M britainBritain
Maravai LifeSciences Holdings Maravai LifeSciences Holdings
MRVI
$ 6.99 -2.85 % $ 1.01 B usaUSA
Lexicon Pharmaceuticals Lexicon Pharmaceuticals
LXRX
$ 1.53 -8.68 % $ 555 M usaUSA
Moleculin Biotech Moleculin Biotech
MBRX
$ 7.73 -2.59 % $ 9.16 M usaUSA
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
TAK
$ 21.79 1.66 % $ 34.4 B japanJapan
Nurix Therapeutics Nurix Therapeutics
NRIX
$ 12.88 -5.29 % $ 1.12 B usaUSA
Nkarta Nkarta
NKTX
$ 1.14 1.34 % $ 84.3 M usaUSA
MacroGenics MacroGenics
MGNX
$ 1.97 -0.76 % $ 124 M usaUSA
Protagonist Therapeutics Protagonist Therapeutics
PTGX
$ 121.72 -2.2 % $ 7.74 B usaUSA
Novo Nordisk A/S Novo Nordisk A/S
NVO
$ 37.8 -2.82 % $ 168 B danmarkDanmark
Marker Therapeutics Marker Therapeutics
MRKR
$ 1.1 -17.05 % $ 16.8 M usaUSA
Arcus Biosciences Arcus Biosciences
RCUS
$ 15.62 -1.01 % $ 1.68 B usaUSA
Replimune Group Replimune Group
REPL
$ 19.07 -0.83 % $ 1.77 B usaUSA
NextCure NextCure
NXTC
$ 6.62 -2.43 % $ 35.2 M usaUSA
Rocket Pharmaceuticals Rocket Pharmaceuticals
RCKT
$ 1.95 -7.82 % $ 217 M usaUSA
PMV Pharmaceuticals PMV Pharmaceuticals
PMVP
$ 0.87 -33.79 % $ 45.7 M usaUSA
United Therapeutics Corporation United Therapeutics Corporation
UTHR
$ 553.08 -1.08 % $ 24.5 B usaUSA
Olema Pharmaceuticals Olema Pharmaceuticals
OLMA
$ 7.0 -2.1 % $ 609 M usaUSA